A new blood test is offering a potentially less invasive and more dynamic approach to breast cancer diagnosis and treatment, according to findings presented at the San Antonio Breast Cancer Symposium. The test, developed by researchers at the Institute of Cancer Research in London, demonstrated up to 90% accuracy in tracking changes in cancer type – a crucial factor in treatment effectiveness – using a simple blood draw. This innovation aims to move beyond traditional tissue biopsies,offering the possibility of more frequent monitoring and personalized treatment adjustments for patients battling this complex disease.
A new blood test developed by a team of British researchers offers a potentially groundbreaking approach to diagnosing and treating breast cancer, allowing for rapid and accurate tumor identification without the need for traditional surgical procedures. Early detection and precise treatment are crucial in improving outcomes for breast cancer patients, and this new test could represent a significant step forward.
The innovative test was trialed at the Institute of Cancer Research in London, demonstrating up to 90% accuracy in detecting changes in cancer type during treatment – a phenomenon that often undermines the effectiveness of medications and complicates treatment plans, according to reports.
A Faster, Less Invasive Alternative
Table of Contents
Currently, doctors rely on tissue samples to determine the type of breast cancer, a process that can be time-consuming and physically and emotionally taxing for patients. The new test analyzes circulating tumor DNA released by cancer cells into the bloodstream, enabling regular monitoring and the development of more flexible and precise treatment plans.
Breast Cancer is Not Static
“The ability to track tumor evolution through the blood may truly transform how we manage this disease,” said Professor Nicholas Turner, Professor of Molecular Oncology. “Breast cancer isn’t static; it changes over time. With this blood analysis, clinicians can adjust treatment at the optimal moment.”
Studies indicate that one in five patients experiences a change in their cancer type during treatment, potentially rendering initial therapies less effective or unsuitable. The current trial revealed that 19% of patients experienced this change, and some analyses even showed the presence of two different types of cancer simultaneously, suggesting the potential for combining two drugs to achieve the best possible response.
Technologies for Other Cancers
The technology behind the test, which centers on DNA analysis, isn’t limited to breast cancer. Experts believe it could serve as a foundation for a new suite of tests to help doctors manage other cancers by detecting early changes in tumors and signals of drug resistance.
“We’ve moved beyond looking at cancer as a single disease; it’s a complex collection of disorders requiring precise and rapid treatment decisions,” said Professor Kristian Helin, Chief Executive of the Institute of Cancer Research. “Any technology that can track resistance to treatment step-by-step is a very important advance.”
Initial Findings
The initial findings, presented at the San Antonio Breast Cancer Symposium, were based on the analysis of 191 blood samples from patients participating in five clinical trials. Scientists are now preparing for a long-term follow-up phase to assess the test’s impact on survival rates and the quality of care within the British National Health Service.
Read also :
